A Long-Term Follow-Up Basket Study for Participants Treated With SynKIR Chimeric Antigen Receptor (CAR) T Cell Product
NCT06701201 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 60
Last updated 2026-02-10
Summary
The primary purpose of this study is to monitor potential long-term risks associated with the administration of SynKIR CAR T cell products.
Conditions
Interventions
- DRUG
-
SynKIR-110
Autologous T cells Transduced with Mesothelin KIR-CAR
- DRUG
-
SynKIR-310
Autologous T Cells transduced with CD19 KIR-CAR
Sponsors & Collaborators
-
Verismo Therapeutics
lead INDUSTRY
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-01-27
- Primary Completion
- 2042-02-28
- Completion
- 2042-02-28
- FDA Drug
- Yes
Countries
- United States
Study Locations
More Related Trials
-
A Study to Evaluate the Safety and Clinical Activity of GF- CART01 (CD20/19 CAR T Cell) in Subjects With Relapsed or Refractory B-Cell Hematological Malignancies
NCT06703892 ·Status: RECRUITING ·Phase: PHASE1
-
A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)
NCT06514794 ·Status: RECRUITING ·Phase: PHASE2
-
Long-term Follow-up of Subjects Exposed to Lentiviral-based CART-EGFRvIII Gene-modified Cellular Therapy Products in Cancer Studies
NCT02666248 ·Status: COMPLETED
-
VitalTraq for the Detection of CRS
NCT06415656 ·Status: COMPLETED ·Phase: NA
-
CAR T Cells Real World Evidence Study Based on the French Hospital Claims Data Source (PMSI)
NCT05349201 ·Status: COMPLETED
-
Autologous CAR-T Cells Targeting B7-H3 in Recurrent or Refractory GBM CAR.B7-H3Tc
NCT05366179 ·Status: RECRUITING ·Phase: PHASE1
-
Chimeric Antigen Receptor T-Cell (CAR-T) Cells in Patients With R/R T-LBL
NCT05554575 ·Status: UNKNOWN ·Phase: PHASE1
-
Phase I Study of Autologous CAR T-Cells Targeting the B7-H3 Antigen in Recurrent Epithelial Ovarian
NCT04670068 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Research Development（RD）13-02 Chimeric Antigen Receptor(CAR) -T Cell Injection for Patients With r/r Cluster Of Differentiation 7（CD7）+ T-Acute Lymphoblastic Leukemia(ALL)/T-Lymphoblastic Lymphoma(LBL) /Acute Myelogenous Leukemia(AML)
NCT05907603 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Bio-CAR-T BS Study
NCT05366569 ·Status: RECRUITING
-
A Study of GC007F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL
NCT03825718 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Treatment of Relapsed and/or Chemotherapy Refractory CD33 Positive Acute Myeloid Leukemia by CART-33
NCT01864902 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
To Observe the Dual-target Chimeric Antigen Receptor T Cells in the Treatment of B Cell Hematologic Tumors
NCT05388695 ·Status: RECRUITING ·Phase: PHASE1
-
CAR-monocytes for the Treatment of HER2 Overexpressing Solid Tumors
NCT06254807 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS
NCT04623944 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Engineered Neuroblastoma Cellular Immunotherapy (ENCIT)-01
NCT02311621 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Ori-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCC
NCT05652920 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Treatment of Relapsed or Refractory B-cell Lymphoma With Chimeric Antigen Receptor (CAR) T-cell Therapy Produced by a New Technology
NCT06378190 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Real-Time Monitoring of Circulating Tumor DNA and Study of Prognostic Factors in Patients Treated With CAR-T Cells
NCT05675982 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
CARTIMMUNE: Study of Patients With Autoimmune Diseases Receiving KYV-101
NCT06152172 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT)
NCT05878184 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Phase 1 Study of HBI0101 CAR-T in Refractory B-Cell Autoimmune Diseases
NCT07085676 ·Status: RECRUITING ·Phase: PHASE1
-
Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With Acute Lymphoblastic Leukemia
NCT02186860 ·Status: UNKNOWN ·Phase: PHASE1
-
A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
NCT05780034 ·Status: RECRUITING ·Phase: PHASE1
-
Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia
NCT05281809 ·Status: RECRUITING ·Phase: PHASE2